Deciphering cellular and molecular mechanism of MUC13 mucin involved in cancer cell plasticity and drug resistance

1.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71, 209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

2.

Urruticoechea, A., Alemany, R., Balart, J., Villanueva, A., Viñals, F., & Capellá, G. (2010). Recent advances in cancer therapy: An overview. Current Pharmaceutical Design, 16, 3–10. https://doi.org/10.2174/138161210789941847CrossRefPubMed

3.

Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K. W. (2012). Cancer and radiation therapy: Current advances and future directions. International Journal of Medical Sciences, 9, 193–199. https://doi.org/10.7150/ijms.3635CrossRefPubMedPubMedCentral

4.

Wang, X., Zhang, H., & Chen, X. (2019). Drug resistance and combating drug resistance in cancer. Cancer Drug Resist, 2, 141–160. https://doi.org/10.20517/cdr.2019.10CrossRefPubMedPubMedCentral

5.

Longley, D. B., & Johnston, P. G. (2005). Molecular mechanisms of drug resistance. The Journal of Pathology, 205, 275–292. https://doi.org/10.1002/path.1706CrossRefPubMed

6.

Smith, L., Watson, M. B., O’Kane, S. L., Drew, P. J., Lind, M. J., & Cawkwell, L. (2006). The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Molecular Cancer Therapeutics, 5, 2115–2120. https://doi.org/10.1158/1535-7163.Mct-06-0190CrossRefPubMed

7.

Harris, L. N., Broadwater, G., Lin, N. U., Miron, A., Schnitt, S. J., Cowan, D., Lara, J., Bleiweiss, I., Berry, D., Ellis, M., et al. (2006). Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: Results from CALGB 9342. Breast Cancer Research, 8, R66. https://doi.org/10.1186/bcr1622CrossRefPubMedPubMedCentral

8.

Murray, S., Briasoulis, E., Linardou, H., Bafaloukos, D., & Papadimitriou, C. (2012). Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies. Cancer Treatment Reviews, 38, 890–903. https://doi.org/10.1016/j.ctrv.2012.02.011CrossRefPubMed

9.

Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006). Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery, 5, 219–234. https://doi.org/10.1038/nrd1984CrossRefPubMed

10.

Vulsteke, C., Pfeil, A. M., Schwenkglenks, M., Pettengell, R., Szucs, T. D., Lambrechts, D., Peeters, M., van Dam, P., Dieudonné, A. S., Hatse, S., et al. (2014). Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel. Breast Cancer Research and Treatment, 147, 557–570. https://doi.org/10.1007/s10549-014-3105-5CrossRefPubMed

11.

Porkka, K., Blomqvist, C., Rissanen, P., Elomaa, I., & Pyrhönen, S. (1994). Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. Journal of Clinical Oncology, 12, 1639–1647. https://doi.org/10.1200/jco.1994.12.8.1639CrossRefPubMed

12.

Sládek, N. E., Kollander, R., Sreerama, L., & Kiang, D. T. (2002). Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: A retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemotherapy and Pharmacology, 49, 309–321. https://doi.org/10.1007/s00280-001-0412-4CrossRefPubMed

13.

Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014). Systems biology of cisplatin resistance: past, present and future. Cell Death Dis, 5, e1257. https://doi.org/10.1038/cddis.2013.428CrossRefPubMedPubMedCentral

14.

Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017). The different mechanisms of cancer drug resistance: A brief review. Advanced Pharmaceutical Bulletin, 7, 339–348. https://doi.org/10.15171/apb.2017.041CrossRefPubMedPubMedCentral

15.

Chang, J. C. (2016). Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance. Medicine (Baltimore), 95, S20-s25. https://doi.org/10.1097/md.0000000000004766CrossRefPubMed

16.

Chen, K., Huang, Y. H., & Chen, J. L. (2013). Understanding and targeting cancer stem cells: Therapeutic implications and challenges. Acta Pharmacologica Sinica, 34, 732–740. https://doi.org/10.1038/aps.2013.27CrossRefPubMedPubMedCentral

17.

Prasad, S., Ramachandran, S., Gupta, N., Kaushik, I., & Srivastava, S. K. (2020). Cancer cells stemness: A doorstep to targeted therapy. Biochimica et Biophysica Acta, Molecular Basis of Disease, 1866, 165424. https://doi.org/10.1016/j.bbadis.2019.02.019CrossRefPubMed

18.

Furth, J., Kahn, M. C., & Breedis, C. (1937). The transmission of leukemia of mice with a single cell. The American Journal of Cancer, 31, 276–282.

19.

Dick, J. E. (2008). Stem cell concepts renew cancer research. Blood, The Journal of the American Society of Hematology, 112, 4793–4807.

20.

Visvader, J. E., & Lindeman, G. J. (2008). Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nature Reviews Cancer, 8, 755–768.CrossRefPubMed

21.

Iwata, M. (1968). Study of serum lipids in infants. 1. Serum lipids in healthy infants. Nihon Shonika Gakkai Zasshi Acta Paediatrica Japonica, 72, 1075–1081.PubMed

22.

Phi, L.T.H., Sari, I.N., Yang, Y.-G., Lee, S.-H., Jun, N., Kim, K.S., Lee, Y.K., Kwon, H.Y. (2018). Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells International, 2018, 5416923. https://doi.org/10.1155/2018/5416923

23.

Shervington, A., & Lu, C. (2008). Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Investigation, 26, 535–542.CrossRefPubMed

24.

Vinogradov, S., & Wei, X. (2012). Cancer stem cells and drug resistance: The potential of nanomedicine. Nanomedicine, 7, 597–615.CrossRefPubMed

25.

Rachagani, S., Torres, M. P., Moniaux, N., & Batra, S. K. (2009). Current status of mucins in the diagnosis and therapy of cancer. BioFactors, 35, 509–527. https://doi.org/10.1002/biof.64CrossRefPubMedPubMedCentral

26.

Reynolds, I. S., Fichtner, M., McNamara, D. A., Kay, E. W., Prehn, J. H. M., & Burke, J. P. (2019). Mucin glycoproteins block apoptosis; promote invasion, proliferation, and migration; and cause chemoresistance through diverse pathways in epithelial cancers. Cancer and Metastasis Reviews, 38, 237–257. https://doi.org/10.1007/s10555-019-09781-wCrossRefPubMed

27.

Dhanisha, S. S., Guruvayoorappan, C., Drishya, S., & Abeesh, P. (2018). Mucins: Structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets. Critical Reviews in Oncology Hematology, 122, 98–122. https://doi.org/10.1016/j.critrevonc.2017.12.006CrossRefPubMed

28.

Brockhausen, I. (2003). Glycodynamics of mucin biosynthesis in gastrointestinal tumor cells. Advances in Experimental Medicine and Biology, 535, 163–188. https://doi.org/10.1007/978-1-4615-0065-0_11CrossRefPubMed

29.

Yonezawa, S., Higashi, M., Yamada, N., Yokoyama, S., Kitamoto, S., Kitajima, S., & Goto, M. (2011). Mucins in human neoplasms: Clinical pathology, gene expression and diagnostic application. Pathology International, 61, 697–716. https://doi.org/10.1111/j.1440-1827.2011.02734.xCrossRefPubMed

30.

Nath, S., & Mukherjee, P. (2014). MUC1: A multifaceted oncoprotein with a key role in cancer progression. Trends in Molecular Medicine, 20, 332–342. https://doi.org/10.1016/j.molmed.2014.02.007CrossRefPubMedPubMedCentral

31.

Moniaux, N., Escande, F., Porchet, N., Aubert, J. P., & Batra, S. K. (2001). Structural organization and classification of the human mucin genes. Frontiers in Bioscience, 6, D1192-1206. https://doi.org/10.2741/moniauxCrossRefPubMed

32.

van Putten, J. P. M., & Strijbis, K. (2017). Transmembrane mucins: Signaling receptors at the intersection of inflammation and cancer. Journal of Innate Immunity, 9, 281–299. https://doi.org/10.1159/000453594CrossRefPubMedPubMedCentral

33.

Chauhan, S. C., Singh, A. P., Ruiz, F., Johansson, S. L., Jain, M., Smith, L. M., Moniaux, N., & Batra, S. K. (2006). Aberrant expression of MUC4 in ovarian carcinoma: Diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Modern Pathology, 19, 1386–1394. https://doi.org/10.1038/modpathol.3800646CrossRefPubMed

34.

Hollingsworth, M. A., & Swanson, B. J. (2004). Mucins in cancer: Protection and control of the cell surface. Nature Reviews Cancer, 4, 45–60. https://doi.org/10.1038/nrc1251CrossRefPubMed

35.

Andrianifahanana, M., Moniaux, N., Schmied, B. M., Ringel, J., Friess, H., Hollingsworth, M. A., Büchler, M. W., Aubert, J. P., & Batra, S. K. (2001). Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: A potential role of MUC4 as a tumor marker of diagnostic significance. Clinical Cancer Research, 7, 4033–4040.PubMed

36.

Balagué, C., Audié, J. P., Porchet, N., & Real, F. X. (1995). In situ hybridization shows distinct patterns of mucin gene expression in normal, benign, and malignant pancreas tissues. Gastroenterology, 109, 953–964. https://doi.org/10.1016/0016-5085(95)90406-9CrossRefPubMed

37.

Dong, Y., Walsh, M. D., Cummings, M. C., Wright, R. G., Khoo, S. K., Parsons, P. G., & McGuckin, M. A. (1997). Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. The Journal of Pathology, 183, 311–317. https://doi.org/10.1002/(sici)1096-9896(199711)183:3%3c311::Aid-path917%3e3.0.Co;2-2CrossRefPubMed

38.

Giuntoli, R. L., Rodriguez, G. C., Whitaker, R. S., Dodge, R., & Voynow, J. A. (1998). Mucin gene expression in ovarian cancers. Cancer Research, 58, 5546–5550.PubMed

39.

Maher, D. M., Gupta, B. K., Nagata, S., Jaggi, M., & Chauhan, S. C. (2011). Mucin 13: Structure, function, and potential roles in cancer pathogenesis. Molecular Cancer Research, 9, 531–537. https://doi.org/10.1158/1541-7786.Mcr-10-0443CrossRefPubMed

40.

Jonckheere, N., Skrypek, N., & Van Seuningen, I. (2014). Mucins and tumor resistance to chemotherapeutic drugs. Biochimica et Biophysica Acta, 1846, 142–151. https://doi.org/10.1016/j.bbcan.2014.04.008CrossRefPubMed

41.

Lee, D.H., Choi, S., Park, Y., Jin, H.S. (2021). Mucin1 and Mucin16: Therapeutic targets for cancer therapy. Pharmaceuticals (Basel), 14. https://doi.org/10.3390/ph14101053.

42.

Ponnusamy, M. P., Seshacharyulu, P., Lakshmanan, I., Vaz, A. P., Chugh, S., & Batra, S. K. (2013). Emerging role of mucins in epithelial to mesenchymal transition. Current Cancer Drug Targets, 13, 945–956. https://doi.org/10.2174/15680096113136660100CrossRefPubMedPubMedCentral

43.

Marimuthu, S., Rauth, S., Ganguly, K., Zhang, C., Lakshmanan, I., Batra, S. K., & Ponnusamy, M. P. (2021). Mucins reprogram stemness, metabolism and promote chemoresistance during cancer progression. Cancer and Metastasis Reviews, 40, 575–588. https://doi.org/10.1007/s10555-021-09959-1CrossRefPubMed

44.

Gendler, S. J., & Spicer, A. P. (1995). Epithelial mucin genes. Annual Review of Physiology, 57, 607–634. https://doi.org/10.1146/annurev.ph.57.030195.003135CrossRefPubMed

45.

Thornton, D. J., Rousseau, K., & McGuckin, M. A. (2008). Structure and function of the polymeric mucins in airways mucus. Annual Review of Physiology, 70, 459–486. https://doi.org/10.1146/annurev.physiol.70.113006.100702CrossRefPubMed

46.

Desseyn, J.-L., Gouyer, V., Tetaert, T. (2008). Architecture of the gel-forming mucins. The Epithelial Mucins: Structure/Function. Roles in Cancer and Inflammatory Diseases, Isabelle Van Seuningen/Research Signpost, 1–16, 978-81-308-0256-5. ⟨hal-02340996⟩.

47.

Hattrup, C. L., & Gendler, S. J. (2008). Structure and function of the cell surface (tethered) mucins. Annual Review of Physiology, 70, 431–457. https://doi.org/10.1146/annurev.physiol.70.113006.100659CrossRefPubMed

48.

Jonckheere, N., Skrypek, N., Frénois, F., & Van Seuningen, I. (2013). Membrane-bound mucin modular domains: From structure to function. Biochimie, 95, 1077–1086. https://doi.org/10.1016/j.biochi.2012.11.005CrossRefPubMed

49.

Jonckheere, N., & Van Seuningen, I. (2008). The membrane-bound mucins: How large O-glycoproteins play key roles in epithelial cancers and hold promise as biological tools for gene-based and immunotherapies. Critical Reviews in Oncogenesis, 14, 177–196. https://doi.org/10.1615/critrevoncog.v14.i2-3.30CrossRefPubMed

50.

Segui-Perez, C., Stapels, D.A.C., Ma, Z., Su, J., Passchier, E., Westendorp, B., Wu, W., Putten, J.P.M.V., Strijbis, K. (2022). MUC13 negatively regulates tight junction proteins and intestinal epithelial barrier integrity via Protein Kinase C. bioRxiv,. https://doi.org/10.1101/2022.10.27.51398

51.

Williams, S. J., Wreschner, D. H., Tran, M., Eyre, H. J., Sutherland, G. R., & McGuckin, M. A. (2001). Muc13, a novel human cell surface mucin expressed by epithelial and hemopoietic cells. Journal of Biological Chemistry, 276, 18327–18336. https://doi.org/10.1074/jbc.M008850200CrossRefPubMed

52.

Chauhan, S. C., Ebeling, M. C., Maher, D. M., Koch, M. D., Watanabe, A., Aburatani, H., Lio, Y., & Jaggi, M. (2012). MUC13 mucin augments pancreatic tumorigenesis. Molecular Cancer Therapeutics, 11, 24–33. https://doi.org/10.1158/1535-7163.Mct-11-0598CrossRefPubMed

53.

Chauhan, S. C., Kumar, D., & Jaggi, M. (2009). Mucins in ovarian cancer diagnosis and therapy. Journal of Ovarian Research, 2, 21. https://doi.org/10.1186/1757-2215-2-21CrossRefPubMedPubMedCentral

54.

Chauhan, S. C., Vannatta, K., Ebeling, M. C., Vinayek, N., Watanabe, A., Pandey, K. K., Bell, M. C., Koch, M. D., Aburatani, H., Lio, Y., et al. (2009). Expression and functions of transmembrane mucin MUC13 in ovarian cancer. Cancer Research, 69, 765–774. https://doi.org/10.1158/0008-5472.Can-08-0587CrossRefPubMed

55.

Gupta, B. K., Maher, D. M., Ebeling, M. C., Stephenson, P. D., Puumala, S. E., Koch, M. R., Aburatani, H., Jaggi, M., & Chauhan, S. C. (2014). Functions and regulation of MUC13 mucin in colon cancer cells. Journal of Gastroenterology, 49, 1378–1391. https://doi.org/10.1007/s00535-013-0885-zCrossRefPubMed

56.

Khan, S., Ebeling, M. C., Zaman, M. S., Sikander, M., Yallapu, M. M., Chauhan, N., Yacoubian, A. M., Behrman, S. W., Zafar, N., Kumar, D., et al. (2014). MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget, 5, 7599–7609. https://doi.org/10.18632/oncotarget.2281CrossRefPubMedPubMedCentral

57.

Khan, S., Sikander, M., Ebeling, M. C., Ganju, A., Kumari, S., Yallapu, M. M., Hafeez, B. B., Ise, T., Nagata, S., Zafar, N., et al. (2017). MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. Oncogene, 36, 491–500. https://doi.org/10.1038/onc.2016.218CrossRefPubMed

58.

Filippou, P. S., Ren, A. H., Korbakis, D., Dimitrakopoulos, L., Soosaipillai, A., Barak, V., Frenkel, S., Pe’er, J., Lotem, M., Merims, S., et al. (2018). Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases. Clinical Chemistry and Laboratory Medicine, 56, 1945–1953. https://doi.org/10.1515/cclm-2018-0139CrossRefPubMed

59.

Khan, S., Zafar, N., Khan, S. S., Setua, S., Behrman, S. W., Stiles, Z. E., Yallapu, M. M., Sahay, P., Ghimire, H., Ise, T., et al. (2018). Clinical significance of MUC13 in pancreatic ductal adenocarcinoma. HPB: The Official Journal of the International Hepato Pancreato Biliary Association, 20, 563–572. https://doi.org/10.1016/j.hpb.2017.12.003CrossRefPubMed

60.

Kumari, S., Khan, S., Gupta, S. C., Kashyap, V. K., Yallapu, M. M., Chauhan, S. C., & Jaggi, M. (2018). MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer. Oncogenesis, 7, 19. https://doi.org/10.1038/s41389-018-0031-0CrossRefPubMedPubMedCentral

61.

Massey, A. E., Doxtater, K. A., Yallapu, M. M., & Chauhan, S. C. (2020). Biophysical changes caused by altered MUC13 expression in pancreatic cancer cells. Micron, 130, 102822. https://doi.org/10.1016/j.micron.2019.102822CrossRefPubMedPubMedCentral

62.

Nishii, Y., Yamaguchi, M., Kimura, Y., Hasegawa, T., Aburatani, H., Uchida, H., Hirata, K., & Sakuma, Y. (2015). A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells. International Journal of Oncology, 46, 1781–1787. https://doi.org/10.3892/ijo.2015.2880CrossRefPubMed

63.

Stiles, Z. E., Khan, S., Patton, K. T., Jaggi, M., Behrman, S. W., & Chauhan, S. C. (2019). Transmembrane mucin MUC13 distinguishes intraductal papillary mucinous neoplasms from non-mucinous cysts and is associated with high-risk lesions. HPB: The Official Journal of the International Hepato Pancreato Biliary Association, 21, 87–95. https://doi.org/10.1016/j.hpb.2018.07.009CrossRefPubMed

64.

Mito, K., Saito, M., Morita, K., Maetani, I., Sata, N., Mieno, M., & Fukushima, N. (2018). Clinicopathological and prognostic significance of MUC13 and AGR2 expression in intraductal papillary mucinous neoplasms of the pancreas. Pancreatology, 18, 407–412. https://doi.org/10.1016/j.pan.2018.04.003CrossRefPubMed

65.

Gupta, B. K., Maher, D. M., Ebeling, M. C., Sundram, V., Koch, M. D., Lynch, D. W., Bohlmeyer, T., Watanabe, A., Aburatani, H., Puumala, S. E., et al. (2012). Increased expression and aberrant localization of mucin 13 in metastatic colon cancer. Journal of Histochemistry and Cytochemistry, 60, 822–831. https://doi.org/10.1369/0022155412460678CrossRefPubMedPubMedCentral

66.

Walsh, M. D., Young, J. P., Leggett, B. A., Williams, S. H., Jass, J. R., & McGuckin, M. A. (2007). The MUC13 cell surface mucin is highly expressed by human colorectal carcinomas. Human Pathology, 38, 883–892. https://doi.org/10.1016/j.humpath.2006.11.020CrossRefPubMed

67.

Kasprzak, A., Adamek, A. (2019). Mucins: The Old, the new and the promising factors in hepatobiliary carcinogenesis. International Journal of Molecular Sciences, 20. https://doi.org/10.3390/ijms20061288

68.

Tiemin, P., Fanzheng, M., Peng, X., Jihua, H., Ruipeng, S., Yaliang, L., Yan, W., Junlin, X., Qingfu, L., Zhefeng, H., et al. (2020). MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways. Journal of Hepatology, 72, 761–773. https://doi.org/10.1016/j.jhep.2019.11.021CrossRefPubMed

69.

Dai, Y., Liu, L., Zeng, T., Liang, J. Z., Song, Y., Chen, K., Li, Y., Chen, L., Zhu, Y. H., Li, J., et al. (2018). Overexpression of MUC13, a poor prognostic predictor, promotes cell growth by activating wnt signaling in hepatocellular carcinoma. American Journal of Pathology, 188, 378–391. https://doi.org/10.1016/j.ajpath.2017.10.016CrossRefPubMed

70.

Pang, Y., Zhang, Y., Zhang, H. Y., Wang, W. H., Jin, G., Liu, J. W., & Zhu, Z. J. (2022). MUC13 promotes lung cancer development and progression by activating ERK signaling. Oncology Letters, 23, 37. https://doi.org/10.3892/ol.2021.13155CrossRefPubMed

71.

Sheng, Y., Ng, C. P., Lourie, R., Shah, E. T., He, Y., Wong, K. Y., Seim, I., Oancea, I., Morais, C., Jeffery, P. L., et al. (2017). MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance. International Journal of Cancer, 140, 2351–2363. https://doi.org/10.1002/ijc.30651CrossRefPubMed

72.

Xu, Z., Liu, Y., Yang, Y., Wang, J., Zhang, G., Liu, Z., Fu, H., Wang, Z., Liu, H., & Xu, J. (2017). High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma. Oncotarget, 8, 7548–7558. https://doi.org/10.18632/oncotarget.13692CrossRefPubMed

73.

Shimamura, T., Ito, H., Shibahara, J., Watanabe, A., Hippo, Y., Taniguchi, H., Chen, Y., Kashima, T., Ohtomo, T., Tanioka, F., et al. (2005). Overexpression of MUC13 is associated with intestinal-type gastric cancer. Cancer Science, 96, 265–273. https://doi.org/10.1111/j.1349-7006.2005.00043.xCrossRefPubMed

74.

He, L., Qu, L., Wei, L., Chen, Y., & Suo, J. (2017). Reduction of miR-132-3p contributes to gastric cancer proliferation by targeting MUC13. Molecular Medicine Reports, 15, 3055–3061. https://doi.org/10.3892/mmr.2017.6347CrossRefPubMedPubMedCentral

75.

Zhao, Z. T., Li, Y., Yuan, H. Y., Ma, F. H., Song, Y. M., & Tian, Y. T. (2020). Identification of key genes and pathways in gastric signet ring cell carcinoma based on transcriptome analysis. World J Clin Cases, 8, 658–669. https://doi.org/10.12998/wjcc.v8.i4.658CrossRefPubMedPubMedCentral

76.

Wang, H., Shen, L., Lin, Y., Shi, Q., Yang, Y., & Chen, K. (2015). The expression and prognostic significance of Mucin 13 and Mucin 20 in esophageal squamous cell carcinoma. Journal of Cancer Research and Therapeutics, 11(Suppl 1), C74-79. https://doi.org/10.4103/0973-1482.163846CrossRefPubMed

77.

Li, P., Wang, H., Hou, M., Li, D., & Bai, H. (2017). Upstream stimulating factor1 (USF1) enhances the proliferation of glioblastoma stem cells mainly by activating the transcription of mucin13 (MUC13). Die Pharmazie, 72, 98–102. https://doi.org/10.1691/ph.2017.6788CrossRefPubMed

78.

Sung, H. Y., Park, A. K., Ju, W., & Ahn, J. H. (2014). Overexpression of mucin 13 due to promoter methylation promotes aggressive behavior in ovarian cancer cells. Yonsei Medical Journal, 55, 1206–1213. https://doi.org/10.3349/ymj.2014.55.5.1206CrossRefPubMedPubMedCentral

79.

Dhasmana, A., Dhasmana, S., Agarwal, S., Khan, S., Haque, S., Jaggi, M., Yallapu, M. M., & Chauhan, S. C. (2023). Integrative big transcriptomics data analysis implicates crucial role of MUC13 in pancreatic cancer. Computational and Structural Biotechnology Journal, 21, 2845–2857. https://doi.org/10.1016/j.csbj.2023.04.029CrossRefPubMedPubMedCentral

80.

Jonckheere, N., Vincent, A., Neve, B., & Van Seuningen, I. (2021). Mucin expression, epigenetic regulation and patient survival: A toolkit of prognostic biomarkers in epithelial cancers. Biochimica et Biophysica Acta - Reviews on Cancer, 1876, 188538. https://doi.org/10.1016/j.bbcan.2021.188538CrossRefPubMed

81.

Thompson, C. M., Cannon, A., West, S., Ghersi, D., Atri, P., Bhatia, R., Smith, L., Rachagani, S., Wichman, C., Kumar, S., et al. (2021). Mucin expression and splicing determine novel subtypes and patient mortality in pancreatic ductal adenocarcinoma. Clinical Cancer Research, 27, 6787–6799. https://doi.org/10.1158/1078-0432.Ccr-21-1591CrossRefPubMed

82.

Fabregas, J. C., Ramnaraign, B., & George, T. J. (2022). Clinical updates for colon cancer care in 2022. Clinical Colorectal Cancer, 21, 198–203. https://doi.org/10.1016/j.clcc.2022.05.006CrossRefPubMed

83.

Byrd, J. C., & Bresalier, R. S. (2004). Mucins and mucin binding proteins in colorectal cancer. Cancer and Metastasis Reviews, 23, 77–99. https://doi.org/10.1023/a:1025815113599CrossRefPubMed

84.

Jonckheere, N., & Van Seuningen, I. (2010). The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers. Biochimie, 92, 1–11. https://doi.org/10.1016/j.biochi.2009.09.018CrossRefPubMed

85.

Cox, K.E., Liu, S., Lwin, T.M., Hoffman, R.M., Batra, S.K., Bouvet, M. (2023). The mucin family of proteins: Candidates as potential biomarkers for colon cancer. Cancers (Basel), 15. https://doi.org/10.3390/cancers15051491.

86.

Sheng, Y. H., He, Y., Hasnain, S. Z., Wang, R., Tong, H., Clarke, D. T., Lourie, R., Oancea, I., Wong, K. Y., Lumley, J. W., et al. (2017). MUC13 protects colorectal cancer cells from death by activating the NF-κB pathway and is a potential therapeutic target. Oncogene, 36, 700–713. https://doi.org/10.1038/onc.2016.241CrossRefPubMed

87.

Sheng, Y. H., Wong, K. Y., Seim, I., Wang, R., He, Y., Wu, A., Patrick, M., Lourie, R., Schreiber, V., Giri, R., et al. (2019). MUC13 promotes the development of colitis-associated colorectal tumors via β-catenin activity. Oncogene, 38, 7294–7310. https://doi.org/10.1038/s41388-019-0951-yCrossRefPubMed

88.

Doxtater, K., Tripathi, M. K., Sekhri, R., Hafeez, B. B., Khan, S., Zafar, N., Behrman, S. W., Yallapu, M. M., Jaggi, M., & Chauhan, S. C. (2023). MUC13 drives cancer aggressiveness and metastasis through the YAP1-dependent pathway. Life Sci Alliance, 6(12). https://doi.org/10.26508/lsa.202301975

89.

Lei, Z. N., Teng, Q. X., Tian, Q., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z. S., et al. (2022). Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduction and Targeted Therapy, 7, 358. https://doi.org/10.1038/s41392-022-01190-wCrossRefPubMedPubMedCentral

90.

Stomach Cancer Survival Rates. The American Cancer Society medical and editorial content team 2023. https://www.cancer.org/cancer/types/stomach-cancer/detection-diagnosis-staging/survival-rates.html

91.

Hepatocellular Carcinoma (HCC). Cleveland Clinic medical professional 2021. https://my.clevelandclinic.org/health/diseases/21709-hepatocellular-carcinoma-hcc

92.

Toh, M. R., Wong, E. Y. T., Wong, S. H., Ng, A. W. T., Loo, L. H., Chow, P. K., & Ngeow, J. (2023). Global Epidemiology and genetics of hepatocellular carcinoma. Gastroenterology, 164, 766–782. https://doi.org/10.1053/j.gastro.2023.01.033CrossRefPubMed

93.

Ganesan, P., & Kulik, L. M. (2023). Hepatocellular carcinoma: New developments. Clinics in Liver Disease, 27, 85–102. https://doi.org/10.1016/j.cld.2022.08.004CrossRefPubMed

94.

Webb, P. M., & Jordan, S. J. (2017). Epidemiology of epithelial ovarian cancer. Best Practice & Research Clinical Obstetrics & Gynaecology, 41, 3–14. https://doi.org/10.1016/j.bpobgyn.2016.08.006CrossRef

95.

Ren, A. H., Filippou, P. S., Soosaipillai, A., Dimitrakopoulos, L., Korbakis, D., Leung, F., Kulasingam, V., Bernardini, M. Q., & Diamandis, E. P. (2023). Mucin 13 (MUC13) as a candidate biomarker for ovarian cancer detection: Potential to complement CA125 in detecting non-serous subtypes. Clinical Chemistry and Laboratory Medicine, 61, 464–472. https://doi.org/10.1515/cclm-2022-0491CrossRefPubMed

96.

Bade, B. C., & Dela Cruz, C. S. (2020). Lung cancer 2020: Epidemiology, etiology, and prevention. Clinics in Chest Medicine, 41, 1–24. https://doi.org/10.1016/j.ccm.2019.10.001CrossRefPubMed

97.

Yang, D., Liu, Y., Bai, C., Wang, X., & Powell, C. A. (2020). Epidemiology of lung cancer and lung cancer screening programs in China and the United States. Cancer Letters, 468, 82–87. https://doi.org/10.1016/j.canlet.2019.10.009CrossRefPubMed

98.

Vaidya, F. U., Sufiyan Chhipa, A., Mishra, V., Gupta, V. K., Rawat, S. G., Kumar, A., & Pathak, C. (2022). Molecular and cellular paradigms of multidrug resistance in cancer. Cancer Rep (Hoboken), 5, e1291. https://doi.org/10.1002/cnr2.1291CrossRefPubMed

99.

Barrera-Rodríguez, R. (2018). Importance of the Keap1-Nrf2 pathway in NSCLC: Is it a possible biomarker? Biomedical Reports, 9, 375–382. https://doi.org/10.3892/br.2018.1143CrossRefPubMedPubMedCentral

100.

Hammerman, P. S., Lawrence, M. S., Voet, D., Jing, R., Cibulskis, K., Sivachenko, A., Stojanov, P., McKenna, A., Lander, E. S., Gabriel, S., Getz, G., Sougnez, C., Imielinski, M., Helman, E., Hernandez, B., Pho, N. H., Meyerson, M., Chu, A., Chun, H.-J. E., et al. Comprehensive genomic characterization of squamous cell lung cancers. PubMed. nih.gov

101.

Giordano, T. J. (2014). The cancer genome atlas research network: A sight to behold. Endocrine Pathology, 25, 362–365. https://doi.org/10.1007/s12022-014-9345-4CrossRefPubMed

102.

Collisson, E. A., Campbell, J. D., Brooks, A. N., Berger, A. H., Lee, W., Chmielecki, J., Beer, D. G., Cope, L., Creighton, C. J., Danilova, L., Ding, L., Getz, G., Hammerman, P. S., Neil Hayes, D., Hernandez, B., Herman, J. G., Heymach, J. V., Jurisica, I., Kucherlapati, R., … John Flynn, H. (2014). Comprehensive molecular profiling of lung adenocarcinoma. Nature, 511(7511), 543–550. https://doi.org/10.1038/nature13385ADSCrossRef

103.

Begicevic, R.R., Falasca, M. (2017). ABC transporters in cancer stem cells: Beyond chemoresistance. International Journal of Molecular Sciences, 18. https://doi.org/10.3390/ijms18112362.

104.

Zhao, J. (2016). Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacology & Therapeutics, 160, 145–158. https://doi.org/10.1016/j.pharmthera.2016.02.008CrossRef

105.

Hasan, S., Taha, R., & Omri, H. E. (2018). Current opinions on chemoresistance: An overview. Bioinformation, 14, 80–85. https://doi.org/10.6026/97320630014080CrossRefPubMedPubMedCentral

106.

Chen, W., Qin, Y., & Liu, S. (2018). Cytokines, breast cancer stem cells (BCSCs) and chemoresistance. Clinical and Translational Medicine, 7, 27. https://doi.org/10.1186/s40169-018-0205-6CrossRefPubMedPubMedCentral

107.

Samuel, S.M., Varghese, E., Koklesová, L., Líšková, A., Kubatka, P., Büsselberg, D. (2020). Counteracting chemoresistance with metformin in breast cancers: Targeting cancer stem cells. Cancers (Basel), 12. https://doi.org/10.3390/cancers12092482.

108.

Nussinov, R., Tsai, C. J., & Jang, H. (2017). A new view of pathway-driven drug resistance in tumor proliferation. Trends in Pharmacological Sciences, 38, 427–437. https://doi.org/10.1016/j.tips.2017.02.001CrossRefPubMedPubMedCentral

109.

Rajabpour, A., Rajaei, F., & Teimoori-Toolabi, L. (2017). Molecular alterations contributing to pancreatic cancer chemoresistance. Pancreatology, 17, 310–320. https://doi.org/10.1016/j.pan.2016.12.013CrossRefPubMed

110.

Alfarouk, K. O., Stock, C. M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Bashir, A. H., Mohammed, O. Y., Elhassan, G. O., Harguindey, S., et al. (2015). Resistance to cancer chemotherapy: Failure in drug response from ADME to P-gp. Cancer Cell International, 15, 71. https://doi.org/10.1186/s12935-015-0221-1CrossRefPubMedPubMedCentral

111.

Moulder, S. (2010). Intrinsic resistance to chemotherapy in breast cancer. Womens Health (Lond), 6, 821–830. https://doi.org/10.2217/whe.10.60CrossRefPubMed

112.

Lippert, T. H., Ruoff, H. J., & Volm, M. (2008). Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittelforschung, 58, 261–264. https://doi.org/10.1055/s-0031-1296504CrossRefPubMed

113.

Schwarzenbach, H., & Gahan, P. B. (2019). Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients. Cancer Drug Resist, 2, 271–296. https://doi.org/10.20517/cdr.2019.010CrossRefPubMedPubMedCentral

114.

Chen, Y., Song, Y., Mi, Y., Jin, H., Cao, J., Li, H., Han, L., Huang, T., Zhang, X., Ren, S., et al. (2020). microRNA-499a promotes the progression and chemoresistance of cervical cancer cells by targeting SOX6. Apoptosis, 25, 205–216. https://doi.org/10.1007/s10495-019-01588-yCrossRefPubMed

115.

Wang, H., Guan, Z., He, K., Qian, J., Cao, J., & Teng, L. (2017). LncRNA UCA1 in anti-cancer drug resistance. Oncotarget, 8, 64638–64650. https://doi.org/10.18632/oncotarget.18344CrossRefPubMedPubMedCentral

116.

Ebrahimi Ghahnavieh, L., Tabatabaeian, H., Ebrahimi Ghahnavieh, Z., Honardoost, M. A., Azadeh, M., Moazeni Bistgani, M., & Ghaedi, K. (2020). Fluctuating expression of miR-584 in primary and high-grade gastric cancer. BMC Cancer, 20, 621. https://doi.org/10.1186/s12885-020-07116-5CrossRefPubMedPubMedCentral

117.

Lim, S. K., Tabatabaeian, H., Lu, S. Y., Kang, S. A., Sundaram, G. M., Sampath, P., Chan, S. W., Hong, W. J., & Lim, Y. P. (2020). Hippo/MST blocks breast cancer by downregulating WBP2 oncogene expression via miRNA processor Dicer. Cell Death & Disease, 11, 669. https://doi.org/10.1038/s41419-020-02901-3CrossRef

118.

Adami, B., Tabatabaeian, H., Ghaedi, K., Talebi, A., Azadeh, M., & Dehdashtian, E. (2019). miR-146a is deregulated in gastric cancer. Journal of Cancer Research and Therapeutics, 15, 108–114. https://doi.org/10.4103/jcrt.JCRT_855_17CrossRefPubMed

119.

Chan, J. J., Tay, Y. (2018). Noncoding RNA:RNA regulatory networks in cancer. The International Journal of Molecular Science, 19. https://doi.org/10.3390/ijms19051310.

120.

Anastasiadou, E., Jacob, L. S., & Slack, F. J. (2018). Non-coding RNA networks in cancer. Nature Reviews Cancer, 18, 5–18. https://doi.org/10.1038/nrc.2017.99CrossRefPubMed

121.

Ramos, E. K., Hoffmann, A. D., Gerson, S. L., & Liu, H. (2017). New opportunities and challenges to defeat cancer stem cells. Trends in cancer, 3, 780–796.CrossRefPubMedPubMedCentral

122.

Singh, A., & Settleman, J. (2010). EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene, 29, 4741–4751.CrossRefPubMedPubMedCentral

123.

Flanagan, D. J., Barker, N., Costanzo, N. S. D., Mason, E. A., Gurney, A., Meniel, V. S., Koushyar, S., Austin, C. R., Ernst, M., & Pearson, H. B. (2019). Frizzled-7 is required for Wnt signaling in gastric tumors with and without Apc mutations. Cancer Research, 79, 970–981.CrossRefPubMed

124.

Zhang, Y., Morris, J. P., IV., Yan, W., Schofield, H. K., Gurney, A., Simeone, D. M., Millar, S. E., Hoey, T., Hebrok, M., & Pasca di Magliano, M. (2013). Canonical wnt signaling is required for pancreatic carcinogenesis. Cancer Research, 73, 4909–4922.CrossRefPubMedPubMedCentral

125.

Sinnberg, T., Levesque, M. P., Krochmann, J., Cheng, P. F., Ikenberg, K., Meraz-Torres, F., Niessner, H., Garbe, C., & Busch, C. (2018). Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype. Molecular Cancer, 17, 1–19.CrossRef

126.

Liu, Y., Chang, Y., Lu, S., & Xiang, Y. Y. (2019). Downregulation of long noncoding RNA DGCR5 contributes to the proliferation, migration, and invasion of cervical cancer by activating Wnt signaling pathway. Journal of Cellular Physiology, 234, 11662–11669.CrossRefPubMed

127.

Veeck, J., Bektas, N., Hartmann, A., Kristiansen, G., Heindrichs, U., Knüchel, R., & Dahl, E. (2008). Wnt signalling in human breast cancer: Expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours. Breast Cancer Research, 10, 1–11.CrossRef

128.

Murillo-Garzón, V., & Kypta, R. (2017). WNT signalling in prostate cancer. Nature Reviews Urology, 14, 683–696.CrossRefPubMed

129.

McCord, M., Mukouyama, Y.-S., Gilbert, M. R., & Jackson, S. (2017). Targeting WNT signaling for multifaceted glioblastoma therapy. Frontiers in cellular neuroscience, 11, 318.CrossRefPubMedPubMedCentral

130.

van Andel, H., Kocemba, K. A., Spaargaren, M., & Pals, S. T. (2019). Aberrant Wnt signaling in multiple myeloma: Molecular mechanisms and targeting options. Leukemia, 33, 1063–1075.CrossRefPubMedPubMedCentral

131.

Ashihara, E., Takada, T., & Maekawa, T. (2015). Targeting the canonical Wnt/β-catenin pathway in hematological malignancies. Cancer Science, 106, 665–671.CrossRefPubMedPubMedCentral

132.

Yadav, A. K., & Desai, N. S. (2019). Cancer stem cells: Acquisition, characteristics, therapeutic implications, targeting strategies and future prospects. Stem Cell Reviews and Reports, 15, 331–355.CrossRefPubMed

133.

Steinbichler, T. B., Dudás, J., Skvortsov, S., Ganswindt, U., Riechelmann, H., & Skvortsova, I. I. (2018). Therapy resistance mediated by cancer stem cells. Seminars in Cancer Biology, 53, 156–167. https://doi.org/10.1016/j.semcancer.2018.11.006CrossRefPubMed

134.

Jaiswal, R., Luk, F., Dalla, P. V., Grau, G. E. R., & Bebawy, M. (2013). Breast cancer-derived microparticles display tissue selectivity in the transfer of resistance proteins to cells. PLoS ONE, 8, e61515.ADSCrossRefPubMedPubMedCentral

135.

Vesel, M., Rapp, J., Feller, D., Kiss, E., Jaromi, L., Meggyes, M., Miskei, G., Duga, B., Smuk, G., & Laszlo, T. (2017). ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling. Respiratory Research, 18, 1–11.CrossRef

136.

Schinkel, A. H., Smit, J. J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P., et al. (1994). Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77, 491–502. https://doi.org/10.1016/0092-8674(94)90212-7CrossRefPubMed

137.

Johnson, W. W. (2002). P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: Modulation of chemotherapy resistance. Methods and Findings in Experimental and Clinical Pharmacology, 24, 501–514. https://doi.org/10.1358/mf.2002.24.8.705071CrossRefPubMed

138.

Cerezo, D., Lencina, M., Ruiz-Alcaraz, A. J., Ferragut, J. A., Saceda, M., Sanchez, M., Cánovas, M., García-Peñarrubia, P., & Martín-Orozco, E. (2012). Acquisition of MDR phenotype by leukemic cells is associated with increased caspase-3 activity and a collateral sensitivity to cold stress. Journal of Cellular Biochemistry, 113, 1416–1425. https://doi.org/10.1002/jcb.24016CrossRefPubMed

139.

Cerezo, D., Ruiz-Alcaraz, A. J., Lencina-Guardiola, M., Cánovas, M., García-Peñarrubia, P., Martínez-López, I., & Martín-Orozco, E. (2017). Attenuated JNK signaling in multidrug-resistant leukemic cells Dual role of MAPK in cell survival. Cell Signal, 30, 162–170. https://doi.org/10.1016/j.cellsig.2016.12.003CrossRefPubMed

140.

Pallis, M., & Russell, N. (2000). P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood, 95, 2897–2904.CrossRefPubMed

141.

Weisburg, J. H., Roepe, P. D., Dzekunov, S., & Scheinberg, D. A. (1999). Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells. Journal of Biological Chemistry, 274, 10877–10888. https://doi.org/10.1074/jbc.274.16.10877CrossRefPubMed

142.

Ding, S., Chamberlain, M., McLaren, A., Goh, L., Duncan, I., & Wolf, C. R. (2001). Cross-talk between signalling pathways and the multidrug resistant protein MDR-1. British Journal of Cancer, 85, 1175–1184. https://doi.org/10.1054/bjoc.2001.2044CrossRefPubMedPubMedCentral

143.

Cerezo, D., Cánovas, M., García-Peñarrubia, P., & Martín-Orozco, E. (2015). Collateral sensitivity to cold stress and differential BCL-2 family expression in new daunomycin-resistant lymphoblastoid cell lines. Experimental Cell Research, 331, 11–20. https://doi.org/10.1016/j.yexcr.2014.11.017CrossRefPubMed

144.

Goler-Baron, V., & Assaraf, Y. G. (2011). Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance. PLoS ONE, 6, e16007. https://doi.org/10.1371/journal.pone.0016007ADSCrossRefPubMedPubMedCentral

145.

Horio, M., Gottesman, M. M., & Pastan, I. (1988). ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proceedings of the National Academy of Sciences of the United States of America, 85, 3580–3584. https://doi.org/10.1073/pnas.85.10.3580ADSCrossRefPubMedPubMedCentral

146.

Leibovitz, A., Stinson, J. C., McCombs, W. B., 3rd., McCoy, C. E., Mazur, K. C., & Mabry Mabry, N. D. (1976). Classification of human colorectal adenocarcinoma cell lines. Cancer Research, 36, 4562–4569.PubMed

147.

Xu, Z., Liu, Y., Yang, Y., Wang, J., Zhang, G., Liu1, Z., Fu, H., Wang, Z., Liu, H., & Xu, J. (2016). High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma. Oncotarget, 8(5), 7548–7558.

148.

Khan, S., Ebeling, M. C., Zaman, M. S., Sikander, M., Yallapu, M. M., Chauhan, N., Yacoubian, A. M., Behrman, S. W., Zafar, N., Kumar, D., et al. (2014). MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget, 5(17), 7599–7609.CrossRefPubMedPubMedCentral

149.

Setua, S., Khan, S., Yallapu, M. M., Behrman, S. W., Sikander, M., Khan, S. S., Jaggi, M., & Chauhan, S. C. (2017). Restitution of tumor suppressor MicroRNA-145 using magnetic nanoformulation for pancreatic cancer therapy. Journal of Gastrointestinal Surgery, 21, 94–105. https://doi.org/10.1007/s11605-016-3222-zCrossRefPubMed

150.

Sikander, M. (2012). Mucins: Potential for ovarian cancer biomarkers. International Journal of Biomedical and Advance Research, 3(6). https://doi.org/10.7439/ijbar.v3i6.526.

151.

Gupta, B. K., Sikander, M., & Jaggi, M. J. (2016). Gastroenterol Dig Dis 1(2). Link: Overview of mucin (MUC13) in gastrointestinal cancers. (https://www.alliedacademies.org/).

152.

Sikander, M., Malik, S., Khan, S., Kumari, S., Chauhan, N., Khan, P., Halaweish, F.T., Chauhan, B., Yallapu, M. M., Jaggi, M., et al. (2019). Novel mechanistic insight into the anticancer activity of cucurbitacin D against pancreatic cancer (Cuc D attenuates pancreatic cancer). Cells, 9. https://doi.org/10.3390/cells9010103.

153.

Mills, J. C., Stanger, B. Z., & Sander, M. (2019). Nomenclature for cellular plasticity: Are the terms as plastic as the cells themselves? EMBO Journal, 38, e103148. https://doi.org/10.15252/embj.2019103148CrossRefPubMedPubMedCentral

154.

Yuan, S., Norgard, R. J., & Stanger, B. Z. (2019). Cellular plasticity in cancer. Cancer Discov, 9, 837–851. https://doi.org/10.1158/2159-8290.Cd-19-0015CrossRefPubMedPubMedCentral

155.

Gurdon, J. B. (1962). The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. Journal of Embryology and Experimental Morphology, 10, 622–640.PubMed

156.

Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126, 663–676. https://doi.org/10.1016/j.cell.2006.07.024CrossRefPubMed

157.

Nieto, M. A., Huang, R. Y., Jackson, R. A., & Thiery, J. P. E. M. T. (2016). Cell, 2016(166), 21–45. https://doi.org/10.1016/j.cell.2016.06.028CrossRef

158.

Shibata, M., Hoque, M.O. (2019). Targeting cancer stem cells: A strategy for effective eradication of cancer. Cancers (Basel), 11 https://doi.org/10.3390/cancers11050732.

159.

Khan, A.Q., Ahmed, E.I., Elareer, N. R., Junejo, K., Steinhoff, M., Uddin, S. (2019). Role of miRNA-regulated cancer stem cells in the pathogenesis of human malignancies. Cells, 8. https://doi.org/10.3390/cells8080840.

160.

Iwata, M. (1968). Study of serum lipids in infants. 1. Serum lipids in healthy infants].Nihon Shonika Gakkai Zasshi, 72, 1075–1081.PubMed

161.

Jordan, C. T., Guzman, M. L., & Noble, M. (2006). Cancer stem cells. New England Journal of Medicine, 355, 1253–1261. https://doi.org/10.1056/NEJMra061808CrossRefPubMed

162.

Thiery, J. P., Acloque, H., Huang, R. Y., & Nieto, M. A. (2009). Epithelial-mesenchymal transitions in development and disease. Cell, 139, 871–890. https://doi.org/10.1016/j.cell.2009.11.007CrossRefPubMed

163.

Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133, 704–715. https://doi.org/10.1016/j.cell.2008.03.027CrossRefPubMedPubMedCentral

164.

Polyak, K., & Weinberg, R. A. (2009). Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nature Reviews Cancer, 9, 265–273. https://doi.org/10.1038/nrc2620CrossRefPubMed

165.

Thiery, J. P. (2003). Epithelial-mesenchymal transitions in development and pathologies. Current Opinion in Cell Biology, 15, 740–746. https://doi.org/10.1016/j.ceb.2003.10.006CrossRefPubMed

166.

Huber, M. A., Kraut, N., & Beug, H. (2005). Molecular requirements for epithelial-mesenchymal transition during tumor progression. Current Opinion in Cell Biology, 17, 548–558. https://doi.org/10.1016/j.ceb.2005.08.001CrossRefPubMed

167.

Malanchi, I., Peinado, H., Kassen, D., Hussenet, T., Metzger, D., Chambon, P., Huber, M., Hohl, D., Cano, A., Birchmeier, W., et al. (2008). Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature, 452, 650–653. https://doi.org/10.1038/nature06835ADSCrossRefPubMed

168.

Peacock, C. D., & Watkins, D. N. (2008). Cancer stem cells and the ontogeny of lung cancer. Journal of Clinical Oncology, 26, 2883–2889. https://doi.org/10.1200/jco.2007.15.2702CrossRefPubMed

169.

Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 3983–3988. https://doi.org/10.1073/pnas.0530291100ADSCrossRefPubMedPubMedCentral

170.

Wielenga, V. J., Smits, R., Korinek, V., Smit, L., Kielman, M., Fodde, R., Clevers, H., & Pals, S. T. (1999). Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. American Journal of Pathology, 154, 515–523. https://doi.org/10.1016/s0002-9440(10)65297-2CrossRefPubMedPubMedCentral

171.

Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., Bruns, C. J., & Heeschen, C. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 1, 313–323. https://doi.org/10.1016/j.stem.2007.06.002CrossRefPubMed

172.

Kumar, R., Gururaj, A. E., & Barnes, C. J. (2006). p21-activated kinases in cancer. Nature Reviews Cancer, 6, 459–471. https://doi.org/10.1038/nrc1892CrossRefPubMed

173.

Coniglio, S. J., Zavarella, S., & Symons, M. H. (2008). Pak1 and Pak2 mediate tumor cell invasion through distinct signaling mechanisms. Molecular and Cellular Biology, 28, 4162–4172. https://doi.org/10.1128/mcb.01532-07CrossRefPubMedPubMedCentral

174.

Boye, K., & Maelandsmo, G. M. (2010). S100A4 and metastasis: A small actor playing many roles. American Journal of Pathology, 176, 528–535. https://doi.org/10.2353/ajpath.2010.090526CrossRefPubMedPubMedCentral

175.

Sherbet, G. V., & Lakshmi, M. S. (1998). S100A4 (MTS1) calcium binding protein in cancer growth, invasion and metastasis. Anticancer Research, 18, 2415–2421.PubMed

176.

Feldner, J. C., & Brandt, B. H. (2002). Cancer cell motility–on the road from c-erbB-2 receptor steered signaling to actin reorganization. Experimental Cell Research, 272, 93–108. https://doi.org/10.1006/excr.2001.5385CrossRefPubMed

177.

Estrella, V., Chen, T., Lloyd, M., Wojtkowiak, J., Cornnell, H. H., Ibrahim-Hashim, A., Bailey, K., Balagurunathan, Y., Rothberg, J. M., Sloane, B. F., et al. (2013). Acidity generated by the tumor microenvironment drives local invasion. Cancer Research, 73, 1524–1535. https://doi.org/10.1158/0008-5472.Can-12-2796CrossRefPubMedPubMedCentral

178.

Walenta, S., Wetterling, M., Lehrke, M., Schwickert, G., Sundfør, K., Rofstad, E. K., & Mueller-Klieser, W. (2000). High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Research, 60, 916–921.PubMed

179.

Weinstein, I. B., & Joe, A. (2008). Oncogene addiction. Cancer Research, 68, 3077–3080. https://doi.org/10.1158/0008-5472.Can-07-3293CrossRefPubMed

180.

Sureshbabu, S. K., Chaukar, D., & Chiplunkar, S. V. (2020). Hypoxia regulates the differentiation and anti-tumor effector functions of γδT cells in oral cancer. Clinical and Experimental Immunology, 201, 40–57. https://doi.org/10.1111/cei.13436CrossRefPubMedPubMedCentral

181.

Zhang, C., Samanta, D., Lu, H., Bullen, J. W., Zhang, H., Chen, I., He, X., & Semenza, G. L. (2016). Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m⁶A-demethylation of NANOG mRNA. Proceedings of the National Academy of Sciences of the United States of America, 113, E2047-2056. https://doi.org/10.1073/pnas.1602883113ADSCrossRefPubMedPubMedCentral

182.

Cao, Z., Zheng, X., Yang, H., Li, S., Xu, F., Yang, X., & Wang, Y. (2020). Association of obesity status and metabolic syndrome with site-specific cancers: A population-based cohort study. British Journal of Cancer, 123, 1336–1344. https://doi.org/10.1038/s41416-020-1012-6CrossRefPubMedPubMedCentral

183.

Ajduković, J. (2016). HIF-1–a big chapter in the cancer tale. Experimental Oncology, 38, 9–12.CrossRefPubMed

184.

Schito, L., & Semenza, G. L. (2016). Hypoxia-inducible factors: Master regulators of cancer progression. Trends Cancer, 2, 758–770. https://doi.org/10.1016/j.trecan.2016.10.016CrossRefPubMed

185.

Mathieu, J., Zhang, Z., Zhou, W., Wang, A. J., Heddleston, J. M., Pinna, C. M., Hubaud, A., Stadler, B., Choi, M., Bar, M., et al. (2011). HIF induces human embryonic stem cell markers in cancer cells. Cancer Research, 71, 4640–4652. https://doi.org/10.1158/0008-5472.Can-10-3320CrossRefPubMedPubMedCentral

186.

Lin, Y. T., & Wu, K. J. (2020). Epigenetic regulation of epithelial-mesenchymal transition: Focusing on hypoxia and TGF-β signaling. Journal of Biomedical Science, 27, 39. https://doi.org/10.1186/s12929-020-00632-3CrossRefPubMedPubMedCentral

187.

Rankin, E. B., Nam, J. M., & Giaccia, A. J. (2016). Hypoxia: Signaling the metastatic cascade. Trends Cancer, 2, 295–304. https://doi.org/10.1016/j.trecan.2016.05.006CrossRefPubMedPubMedCentral

188.

Hajizadeh, F., Okoye, I., Esmaily, M., Ghasemi Chaleshtari, M., Masjedi, A., Azizi, G., Irandoust, M., Ghalamfarsa, G., & Jadidi-Niaragh, F. (2019). Hypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells. Life Sciences, 237, 116952. https://doi.org/10.1016/j.lfs.2019.116952CrossRefPubMed

189.

Zhang, H., Lu, H., Xiang, L., Bullen, J. W., Zhang, C., Samanta, D., Gilkes, D. M., He, J., & Semenza, G. L. (2015). HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proceedings of the National Academy of Sciences of the United States of America, 112, E6215-6223. https://doi.org/10.1073/pnas.1520032112ADSCrossRefPubMedPubMedCentral

190.

Thomas, S., Harding, M. A., Smith, S. C., Overdevest, J. B., Nitz, M. D., Frierson, H. F., Tomlins, S. A., Kristiansen, G., & Theodorescu, D. (2012). CD24 is an effector of HIF-1-driven primary tumor growth and metastasis. Cancer Research, 72, 5600–5612. https://doi.org/10.1158/0008-5472.Can-11-3666CrossRefPubMedPubMedCentral

191.

Ohnishi, S., Maehara, O., Nakagawa, K., Kameya, A., Otaki, K., Fujita, H., Higashi, R., Takagi, K., Asaka, M., Sakamoto, N., et al. (2013). hypoxia-inducible factors activate CD133 promoter through ETS family transcription factors. PLoS ONE, 8, e66255. https://doi.org/10.1371/journal.pone.0066255ADSCrossRefPubMedPubMedCentral

192.

Hashimoto, O., Shimizu, K., Semba, S., Chiba, S., Ku, Y., Yokozaki, H., & Hori, Y. (2011). Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1α-dependent manner in pancreatic cancer cells. Pathobiology, 78, 181–192. https://doi.org/10.1159/000325538CrossRefPubMed

193.

Chiu, D. K., Zhang, M. S., Tse, A. P., & Wong, C. C. (2019). Assessment of stabilization and activity of the HIFs important for hypoxia-induced signalling in cancer cells. Methods in Molecular Biology, 1928, 77–99. https://doi.org/10.1007/978-1-4939-9027-6_6CrossRefPubMed

194.

Soeda, A., Park, M., Lee, D., Mintz, A., Androutsellis-Theotokis, A., McKay, R. D., Engh, J., Iwama, T., Kunisada, T., Kassam, A. B., et al. (2009). Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene, 28, 3949–3959. https://doi.org/10.1038/onc.2009.252CrossRefPubMed

195.

Xiang, L., & Semenza, G. L. (2019). Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy. Advances in Cancer Research, 141, 175–212. https://doi.org/10.1016/bs.acr.2018.11.001CrossRefPubMed

196.

Porta, C., Paglino, C., & Mosca, A. (2014). Targeting PI3K/Akt/mTOR signaling in cancer. Frontiers in Oncology, 4, 64. https://doi.org/10.3389/fonc.2014.00064CrossRefPubMedPubMedCentral

197.

Li, H., Zeng, J., & Shen, K. (2014). PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. Archives of Gynecology and Obstetrics, 290, 1067–1078. https://doi.org/10.1007/s00404-014-3377-3CrossRefPubMed

198.

Tapia, O., Riquelme, I., Leal, P., Sandoval, A., Aedo, S., Weber, H., Letelier, P., Bellolio, E., Villaseca, M., Garcia, P., et al. (2014). The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Archiv, 465, 25–33. https://doi.org/10.1007/s00428-014-1588-4CrossRefPubMed

199.

Honjo, S., Ajani, J. A., Scott, A. W., Chen, Q., Skinner, H. D., Stroehlein, J., Johnson, R. L., & Song, S. (2014). Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. International Journal of Oncology, 45, 567–574. https://doi.org/10.3892/ijo.2014.2450CrossRefPubMedPubMedCentral

200.

Mohammed, A., Janakiram, N. B., Brewer, M., Ritchie, R. L., Marya, A., Lightfoot, S., Steele, V. E., & Rao, C. V. (2013). Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Transl Oncol, 6, 649–659. https://doi.org/10.1593/tlo.13556CrossRefPubMedPubMedCentral

201.

Chang, L., Graham, P. H., Hao, J., Ni, J., Bucci, J., Cozzi, P. J., Kearsley, J. H., & Li, Y. (2013). Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death & Disease, 4, e875. https://doi.org/10.1038/cddis.2013.407CrossRef

202.

Zhou, J., Wulfkuhle, J., Zhang, H., Gu, P., Yang, Y., Deng, J., Margolick, J. B., Liotta, L. A., Petricoin, E., 3rd., & Zhang, Y. (2007). Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proceedings of the National Academy of Sciences of the United States of America, 104, 16158–16163. https://doi.org/10.1073/pnas.0702596104ADSCrossRefPubMedPubMedCentral

203.

Douville, J., Beaulieu, R., & Balicki, D. (2009). ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev, 18, 17–25. https://doi.org/10.1089/scd.2008.0055CrossRefPubMed

204.

Huang, E. H., Hynes, M. J., Zhang, T., Ginestier, C., Dontu, G., Appelman, H., Fields, J. Z., Wicha, M. S., & Boman, B. M. (2009). Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Research, 69, 3382–3389. https://doi.org/10.1158/0008-5472.Can-08-4418CrossRefPubMedPubMedCentral

205.

Nishitani, S., Horie, M., Ishizaki, S., & Yano, H. (2013). Branched chain amino acid suppresses hepatocellular cancer stem cells through the activation of mammalian target of rapamycin. PLoS ONE, 8, e82346. https://doi.org/10.1371/journal.pone.0082346ADSCrossRefPubMedPubMedCentral

206.

Sunayama, J., Matsuda, K., Sato, A., Tachibana, K., Suzuki, K., Narita, Y., Shibui, S., Sakurada, K., Kayama, T., Tomiyama, A., et al. (2010). Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells, 28, 1930–1939. https://doi.org/10.1002/stem.521CrossRefPubMed

207.

Bleau, A. M., Hambardzumyan, D., Ozawa, T., Fomchenko, E. I., Huse, J. T., Brennan, C. W., & Holland, E. C. (2009). PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell, 4, 226–235. https://doi.org/10.1016/j.stem.2009.01.007CrossRefPubMedPubMedCentral

At a glance: The STEP trials

Springer Medicine

Deciphering cellular and molecular mechanism of MUC13 mucin involved in cancer cell plasticity and drug resistance

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer